PURPOSE: Psoriasin (S100A7) is highly expressed in preinvasive ductal carcinoma in situ of the breast and persistent expression occurs in some invasive carcinomas. This study explores the clinical significance of psoriasin in relation to patient survival in invasive breast cancer. EXPERIMENTAL DESIGN: We examined psoriasin expression by immunohistochemistry in a cohort of 122 estrogen receptor-negative invasive ductal carcinomas. RESULTS: Psoriasin expression was observed in 64 of 122 cases (52%) but was not correlated with other prognostic factors (including progesterone receptor, stage, size, grade, and nodal status) within this cohort. However, in univariate analysis, psoriasin expression (nuclear and cytoplasmic) was associated with a shorter time to progression (P < 0.04) and poor survival (P < 0.03). In multivariate analysis, cytoplasmic psoriasin also emerged as independent indicator of time to progression (hazard ratio, 1.86; 95% confidence interval, 1.02-3.39; P = 0.044) and survival (hazard ratio, 2.12; 95% confidence interval, 1.06-4.23; P = 0.033). CONCLUSIONS: These results suggest that psoriasin expression may be associated with a worse prognosis in estrogen receptor-negative invasive ductal carcinomas and raise the possibility that psoriasin expression may also be an indicator of risk of progression in ductal carcinoma in situ.
PURPOSE: Psoriasin (S100A7) is highly expressed in preinvasive ductal carcinoma in situ of the breast and persistent expression occurs in some invasive carcinomas. This study explores the clinical significance of psoriasin in relation to patient survival in invasive breast cancer. EXPERIMENTAL DESIGN: We examined psoriasin expression by immunohistochemistry in a cohort of 122 estrogen receptor-negative invasive ductal carcinomas. RESULTS: Psoriasin expression was observed in 64 of 122 cases (52%) but was not correlated with other prognostic factors (including progesterone receptor, stage, size, grade, and nodal status) within this cohort. However, in univariate analysis, psoriasin expression (nuclear and cytoplasmic) was associated with a shorter time to progression (P < 0.04) and poor survival (P < 0.03). In multivariate analysis, cytoplasmic psoriasin also emerged as independent indicator of time to progression (hazard ratio, 1.86; 95% confidence interval, 1.02-3.39; P = 0.044) and survival (hazard ratio, 2.12; 95% confidence interval, 1.06-4.23; P = 0.033). CONCLUSIONS: These results suggest that psoriasin expression may be associated with a worse prognosis in estrogen receptor-negative invasive ductal carcinomas and raise the possibility that psoriasin expression may also be an indicator of risk of progression in ductal carcinoma in situ.
Authors: Mohd W Nasser; Zahida Qamri; Yadwinder S Deol; Janani Ravi; Catherine A Powell; Prashant Trikha; Reto A Schwendener; Xue-Feng Bai; Konstantin Shilo; Xianghong Zou; Gustavo Leone; Ronald Wolf; Stuart H Yuspa; Ramesh K Ganju Journal: Cancer Res Date: 2011-12-12 Impact factor: 12.701
Authors: Amita Sneh; Yadwinder S Deol; Akaansha Ganju; Konstantin Shilo; Thomas J Rosol; Mohd W Nasser; Ramesh K Ganju Journal: Breast Cancer Res Treat Date: 2013-03-28 Impact factor: 4.872
Authors: Anne A Blanchard; George P Skliris; Peter H Watson; Leigh C Murphy; Carla Penner; Ladislav Tomes; Tamara L Young; Etienne Leygue; Yvonne Myal Journal: Virchows Arch Date: 2009-04-23 Impact factor: 4.064
Authors: Nathan R West; Benjamin Farnell; Jill I Murray; Fraser Hof; Peter H Watson; Martin J Boulanger Journal: Protein Sci Date: 2009-12 Impact factor: 6.725
Authors: Ronald Wolf; Christopher Voscopoulos; Jason Winston; Alif Dharamsi; Paul Goldsmith; Michele Gunsior; Barbara K Vonderhaar; Melanie Olson; Peter H Watson; Stuart H Yuspa Journal: Cancer Lett Date: 2009-01-10 Impact factor: 8.679
Authors: Ran Xie; Matthew P Schlumbrecht; Gregory L Shipley; Susu Xie; Roland L Bassett; Russell R Broaddus Journal: Lab Invest Date: 2009-06-08 Impact factor: 5.662